Annett Keller

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes

Julio Rosenstock, Steven E. Kahn, Odd Erik Johansen et al. · JAMA · 2019 · 606 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

High Cellular Monocyte Activation in People Living With Human Immunodeficiency Virus on Combination Antiretroviral Therapy and Lifestyle-Matched Controls Is Associated With Greater Inflammation in Cerebrospinal Fluid

Thijs Booiman, Ferdinand W.N.M. Wit, Irma Maurer et al. · Open Forum Infectious Diseases · 2017 · 33 citations · Full text

Life Sciences, Immunology, Infectious Diseases +16

Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized <scp>CAROLINA</scp> trial

Mark A. Espeland, Richard E. Pratley, Julio Rosenstock et al. · Diabetes Obesity and Metabolism · 2020 · 30 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial

Gilbert Ledesma, Guillermo E. Umpierrez, John E. Morley et al. · Diabetes Obesity and Metabolism · 2019 · 28 citations

Medicine, Endocrinology, Geriatric Medicine +17

Exploratory study of premenstrual symptoms and serotonin variability

Anita H. Clayton, Annett Keller, Carine E. Leslie et al. · Archives of Women s Mental Health · 2005 · 22 citations

Medicine, Gynecology, Psychiatry +16